|Bid||1.65 x 1000|
|Ask||1.95 x 500|
|Day's Range||1.70 - 1.75|
|52 Week Range||1.35 - 8.00|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CHESTERBROOK, Pa., Jan. 02, 2018-- Trevena, Inc. today announced that the U.S. Food and Drug Administration has accepted the Company’ s New Drug Application for OLINVO™ Injection. The Company expects that ...
CHESTERBROOK, Pa., Nov. 02, 2017-- Trevena, Inc. today announced that it has recently submitted its New Drug Application for OLINVO TM to the U.S. OLINVO is the first G protein biased ligand of the mu ...
CHESTERBROOK, Pa., Nov. 01, 2017-- Trevena, Inc. today announced that it will host a conference call and webcast on Tuesday, November 7, 2017 at 8:00 am EST to review financial results for the quarter ...
NEW YORK, March 24, 2017 /PRNewswire/ -- Argos Therapeutics, Inc. (ARGS) Lifshitz & Miller announces investigation on behalf of ARGS investors concerning whether ARGS overstated the potential of its developmental ...
NEW YORK, March 15, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Trevena, Inc. ("Trevena" or the ...
SAN DIEGO, March 15, 2017 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP has commenced an investigation of Trevena, Inc. (NASDAQ: TRVN) concerning possible violations of federal securities ...
Holzer & Holzer, LLC is investigating whether certain statements issued by Trevena, Inc. complied with federal securities laws. On February 21, 2017, Trevena announced the clinical trial results for its morphine-alternative drug, Oliceridine, which revealed that the drug did not have statistically significant rates of higher tolerability or safety as compared to standard morphine.